Although primary splenic angiosarcoma typically has a poor prognosis, multimodality management can achieve durable benefit and prolonged disease stabilization in some patients.
No takes yet. Share an insight, caveat, or question.
May support multimodality therapy in select splenic angiosarcoma cases; leaves open need for prospective validation.
Kohútek et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: